{"id":"sitagliptin-standard-prophylaxis","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL1201174","moleculeType":"Small molecule","molecularWeight":"523.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sitagliptin is a DPP-4 inhibitor that prevents the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby prolonging their action. This leads to glucose-dependent stimulation of insulin secretion and inhibition of glucagon release, resulting in improved glycemic control. The 'Standard Prophylaxis' component likely refers to standard preventive measures in the trial context, possibly infection prophylaxis or other supportive care.","oneSentence":"Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and stimulate insulin secretion in response to glucose.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:53:06.240Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus (in combination with standard prophylaxis, likely in a specific clinical context such as perioperative or infection prevention setting)"}]},"trialDetails":[{"nctId":"NCT07436663","phase":"PHASE4","title":"Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2026-02-01","conditions":"Breast Cancer","enrollment":150},{"nctId":"NCT05149365","phase":"PHASE3","title":"Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-12-22","conditions":"Acute-graft-versus-host Disease, Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":190},{"nctId":"NCT02556918","phase":"PHASE4","title":"Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-01","conditions":"Hyperglycemia","enrollment":202},{"nctId":"NCT02741687","phase":"PHASE4","title":"Sitagliptin in Non-Diabetic Patients Undergoing General Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-06","conditions":"Hyperglycemia","enrollment":80},{"nctId":"NCT02443402","phase":"PHASE4","title":"Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-01","conditions":"Coronary Artery Disease","enrollment":68},{"nctId":"NCT01974544","phase":"NA","title":"Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2013-05","conditions":"Type 2 Diabetes","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cyclosporine (CsA),Methotrexate (MTX), Mycopherol ester (MMF) and Antithymic Globulin"],"phase":"phase_3","status":"active","brandName":"Sitagliptin + Standard Prophylaxis","genericName":"Sitagliptin + Standard Prophylaxis","companyName":"The First Affiliated Hospital of Soochow University","companyId":"the-first-affiliated-hospital-of-soochow-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sitagliptin is a small molecule dipeptidyl peptidase 4 inhibitor used to treat conditions such as hyperglycemia and type 2 diabetes. It is typically used in conjunction with standard prophylaxis, which may include supplemental insulin, to manage these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}